European Commission names companies in EU pay-for-delay probe
This article was originally published in SRA
The European Commission has fired warning shots at Lundbeck and Servier in its long-running probe into the possibility that pharmaceutical companies have engaged in anti-competitive business practices1,2. This is the first case that may lead to commission action against companies for "pay-for-delay" tactics to keep competing generic products off the market.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.